More info…
TEL AVIV (MarketWatch) — Forest Laboratories Inc. and Gedeon Richter PLC said Monday that in a Phase II study of cariprazine, a potential treatment for bipolar depression, the overall result for patients taking the drug was not statistically different from that of the patients taking placebo. In higher doses, however, the antipsychotic drug did show “evidence of a clinically relevant treatment …
September 1, 2010 By Leave a Comment
Forest-Gedeon Richter drug misses overall goal
Speak Your Mind
You must be logged in to post a comment.